Archives of Advances in Biosciences

[1] Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. J Breast Imaging. 2021;3(1):12-24. [DOI: 10.1093/jbi/wbaa110] [PMID]

[2] Zhang MH, Man HT, Zhao XD, Dong N, Ma SL. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials. Biomed Rep. 2014;2(1):41-52. [DOI: 10.3892/br.2013.187] [PMID]

[3] Zubair M, Riaz M, Kiani MN, Aslam HM, Fatima AEZ, Sultan HM, et al. Application of nanotechnology for targeted drug delivery and nontoxicity. International Journal of General Practice Nursing. 2024;2(2):57-67. [DOI: 10.26689/ijgpn.v2i2.7436]

[4] Maryam S, Rasheed M, Kareem K, Javed I, Amjad M, Sultan H. Synthesis and function of multi-modality probe for early tumor diagnosis in mouse. Alq J Med App Sci. 2021;4(2):152-62. [DOI: 10.5281/zenodo.5160205]

[5] Tufail M, Wu C. Exploring the burden of cancer in Pakistan: an analysis of 2019 data. J Epidemiol Glob Health. 2023;13(2):333-43. [DOI: 10.1007/s44197-023-00104-5] [PMID]

[6] Sultan HM, Fatima M, Rehman BU, Sajid T, Riaz M, Mustafa FE, et al. Advances in the probiotic production, innovation, and therapeutic applications in health and nutrition. Trends in Infection and Global Health. 2024;4(2):31-49. [DOI: 10.24815/tigh.v4i2.42582]

[7] Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021;13(11):2824. [DOI: 10.3390/cancers13112824] [PMID]

[8] Chen M, Chen W, Liu D, Chen W, Shen K, Wu J, et al. Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer. Breast Cancer. 2022;29(5):844-53. [DOI: 10.1007/s12282-022-01364-y] [PMID]

[9] Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129. [DOI: 10.1186/s13045-022-01347-8] [PMID]

[10] Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, et al. Autophagy and EMT in cancer and metastasis: who controls whom? Biochim Biophys Acta Mol Basis Dis. 2022;1868(9):166431. [DOI: 10.1016/j.bbadis.2022.166431] [PMID]

[11] Sajid T, Khan J, Abbas Z, Sultan HM, Mazhar M, Zubair M, et al. Targeting cancers: uncovering the potential roles of potato tissue culture as anti-cancer agents. Proceedings of Anticancer Research. 2024;8(3):36-50. [DOI: 10.26689/par.v8i3.6756]

[12] Ali M, Shabbir K, Ali S, Mohsin M, Kumar A, Aziz M, et al. A new era of discovery: how artificial intelligence has revolutionized the biotechnology. Nepal J Biotechnol. 2024;12(1):1-11. [DOI: 10.54796/njb.v12i1.312]

[13] Rasheed M, Kareem K, Liaquat A, Ashraf A, Maryam S. Qualitative proteomics analysis of proteins and biomarkers of Alzheimer's disease. ASEAN Journal of Science and Engineering. 2022;2(3):217-30. [DOI: 10.17509/ajse.v2i3.39391]

[14] Shazma, Zubair M, Sultan HM, Rehman BU, Ahmed U, Zehra F, et al. CRISPR-Cas9: a promising therapeutic approach for diabetes mellitus. International Journal of General Practice Nursing. 2024;2(2):43-56. [DOI: 10.26689/ijgpn.v2i2.7433]

[15] Piergentili R, Basile G, Nocella C, Carnevale R, Marinelli E, Patrone R, et al. Using ncRNAs as tools in cancer diagnosis and treatment—the way towards personalized medicine to improve patients' health. Int J Mol Sci. 2022;23(16):9353. [DOI: 10.3390/ijms23169353] [PMID]

[16] Abubakar M, Ayyoub R, Rehman B, Kiani MN, Ahmed U, Farooq J, et al. Exploring novel therapeutic breakthroughs for cancers: potential roles of miRNAs. Proceedings of Anticancer Research. 2024;8(5):11-24. [DOI: 10.26689/par.v8i5.6924]

[17] Sultan H, Javed I, Zubair M, Iqbal K, Bilal M, Iqbal J, et al. Protein and polysaccharide base biomaterial for the formation of composite bone scaffold. Alq J Med App Sci. 2021;4(2):80-8. [DOI: 10.5281/zenodo.4917928]

[18] Khalid A, Sultan HM. Anthelmintic activity of Foeniculum vulgare seeds and meta-analysis of some other medicinal plants from Pakistan. International Journal of General Practice Nursing. 2024;2(2):34-42. [DOI: 10.26689/ijgpn.v2i2.7432]

[19] Yousaf A, Tasneem N, Mustafa A, Fatima R, Nabia N, Khan RA, et al. Gastric cancer associated risk factors and prevalence in Pakistan. ASEAN Journal of Science and Engineering. 2021;1(2):73-8. [DOI: 10.17509/ajse.v1i2.41124]

[20] Riaz M, Zubair M, Iqbal MK, Bukhari SMA, Sultan HM. Exploring the platelet and cancer cell interaction in metastasis targeting. Journal of Current Oncology and Medical Sciences. 2024;4(2):834-44. [LINK]

[21] Li Y, Li W, Hoffman AR, Cui J, Hu JF. The nucleus/mitochondria-shuttling lncRNAs function as new epigenetic regulators of mitophagy in cancer. Front Cell Dev Biol. 2021;9:699621. [DOI: 10.3389/fcell.2021.699621] [PMID]

[22] Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Ther. 2022;29(12):1866-77. [DOI: 10.1038/s41417-022-00487-w] [PMID]

[23] Tang J, Wang X, Xiao D, Liu S, Tao Y. The chromatin-associated RNAs in gene regulation and cancer. Mol Cancer. 2023;22(1):27. [DOI: 10.1186/s12943-023-01724-y] [PMID]

[24] Salah Eldeen YM, Ibrahim MM, Kamal DE, AlKaramany AS. Long non-coding RNA Hox transcript antisense intergenic RNA (HOTAIR) possible roles in rheumatoid arthritis. Zagazig Univ Med J. 2025;31(2):866-75. [LINK]

[25] Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 2018;485:229-33. [DOI: 10.1016/j.cca.2018.07.004] [PMID]

[26] Song Y, Wang Y, Chen M, Wei Z. HOX transcript antisense intergenic RNA is differentially expressed in hypertrophic scar tissues and regulates the biological function of scar fibroblasts through sponging miR-30a-5p. Dermatol Sin. 2023;41(3):160-5. [DOI: 10.4103/ds.DS-D-22-00120]

[27] Liguori G, Cerrone M, De Chiara A, Tafuto S, de Bellis MT, Botti G, et al. The role of lncRNAs in rare tumors with a focus on Hox transcript antisense RNA (HOTAIR). Int J Mol Sci. 2021;22(18):10160. [DOI: 10.3390/ijms221810160] [PMID]

[28] Aftab Z, Bukhari SMA, Abubakar M, Sultan HM, Zubair M, Abou El Niaaj MA. Innovative nanoparticle synthesis and multifaceted applications in medicine and cancer therapy. Journal of Clinical and Nursing Research. 2024;8(11):21-35. [DOI: 10.26689/jcnr.v8i11.8728]

[29] Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat Rev Genet. 2011;12(4):283-93. [DOI: 10.1038/nrg2957] [PMID]

[30] Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012;13(9):613-26. [DOI: 10.1038/nrg3207] [PMID]

[31] Ntini E, Louloupi A, Liz J, Muino JM, Marsico A, Ørom UA. Long ncRNA A-ROD activates its target gene DKK1 at its release from chromatin. Nat Commun. 2018;9(1):1636. [DOI: 10.1038/s41467-018-04100-3] [PMID]

[32] Di M, Zhang Y, Zeng R, Liu X, Chen W, Zhang M, et al. The pro-angiogenesis effect of miR33a-5p/Ets-1/DKK1 signaling in ox-LDL induced HUVECs. Int J Biol Sci. 2021;17(15):4122-39. [DOI: 10.7150/ijbs.60302] [PMID] [PMCID]

[33] Giuliani B, Tordonato C, Nicassio F. Mechanisms of long non-coding RNA in breast cancer. Int J Mol Sci. 2023;24(5):4538. [DOI: 10.3390/ijms24054538] [PMID]

[34] Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nat Rev Genet. 2020;21(2):102-17. [DOI: 10.1038/s41576-019-0184-5] [PMID]

[35] Pirlog R, Drula R, Nutu A, Calin GA, Berindan-Neagoe I. The roles of the colon cancer associated transcript 2 (CCAT2) long non-coding RNA in cancer: a comprehensive characterization of the tumorigenic and molecular functions. Int J Mol Sci. 2021;22(22):12491. [DOI: 10.3390/ijms222212491] [PMID]

[36] Liau XL, Salvamani S, Gunasekaran B, Chellappan DK, Rhodes A, Ulaganathan V, et al. CCAT1—a pivotal oncogenic long non-coding RNA in colorectal cancer. Br J Biomed Sci. 2023;80:11103. [DOI: 10.3389/bjbs.2023.11103] [PMID]

[37] Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24(5):513-31. [DOI: 10.1038/cr.2014.35] [PMID]

[38] Zhao W, Song M, Zhang J, Kuerban M, Wang H. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. Int J Clin Exp Pathol. 2015;8(11):14131-40. [PMID] [PMCID]

[39] Ozawa T, Matsuyama T, Toiyama Y, Takahashi N, Ishikawa T, Uetake H, et al. CCAT1 and CCAT2 long noncoding RNAs, located within the 8q24.21 'gene desert,' serve as important prognostic biomarkers in colorectal cancer. Ann Oncol. 2017;28(8):1882-8. [DOI: 10.1093/annonc/mdx248] [PMID]

[40] Rehman B, Abubakar M, Kiani MN, Ayyoub R. Analysis of genetic alterations in TP53 gene in breast cancer. Proceedings of Anticancer Research. 2024;8(3):25-35. https://doi.org/10.26689/par.v8i3.6720

[41] Xie X, Tang B, Xiao YF, Xie R, Li BS, Dong H, et al. Long non-coding RNAs in colorectal cancer. Oncotarget. 2016;7(5):5226-39. https://doi.org/10.18632/oncotarget.6446. [PMID] [PMCID]

[42] Wang Y, Liu J, Huang BO, Xu YM, Li J, Huang LF, et al. Mechanism of alternative splicing and its regulation. Biomed Rep. 2015;3(2):152-8. [DOI: 10.3892/br.2014.407] [PMID]

[43] Fernandes JC, Acuña SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA. 2019;5(1):17. [DOI: 10.3390/ncrna5010017] [PMID]

[44] Athie-Cuervo A. Somatic copy-number alterations across human cancers from lncRNA perspective [doctoral dissertation]. Pamplona: Universidad de Navarra; 2017. [LINK]

[45] Hasler D, Meister G, Fischer U. Stabilize and connect: the role of LARP7 in nuclear non-coding RNA metabolism. RNA Biol. 2021;18(2):290-303. [DOI: 10.1080/15476286.2020.1767952] [PMID]

[46] Zhao P. Multi-omics approaches to elucidate the role of non-coding genome in cancer [doctoral dissertation]. Leuven: KU Leuven; 2023. [LINK]

[47] De Troyer L, Zhao P, Pastor T, Baietti MF, Barra J, Vendramin R, et al. Stress-induced lncRNA LASTR fosters cancer cell fitness by regulating the activity of the U4/U6 recycling factor SART3. Nucleic Acids Res. 2020;48(5):2502-17. [DOI: 10.1093/nar/gkz1237] [PMID]

[48] Zhou ZR, Wang XY, Yu XL, Mei X, Chen XX, Hu QC, et al. Building radiation-resistant model in triple-negative breast cancer to screen radioresistance-related molecular markers. Ann Transl Med. 2020;8(4):108. [DOI: 10.21037/atm.2019.12.114] [PMID] [PMCID]

[49] Kumar V, Shaulian E. LncRNAs, critical regulators of cellular stress in cancer: a new player in the old game. J Cell Signal. 2024;5(3):143-8. [DOI: 10.33696/Signaling.5.120]

[50] Jen J, Tang YA, Lu YH, Lin CC, Lai WW, Wang YC. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer. 2017;16(1):104. [DOI: 10.1186/s12943-017-0674-z] [PMID]

[51] Sun Y, Ma L. New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel). 2019;11(2):216. [DOI: 10.3390/cancers11020216] [PMID]

[52] Alshahrani MY, Saleh RO, Hjazi A, Bansal P, Kaur H, Deorari M, et al. Molecular mechanisms of tumorgenesis and metastasis of long non-coding RNA (lncRNA) NEAT1 in human solid tumors; an update. Cell Biochem Biophys. 2024;82(2):593-607. [DOI: 10.1007/s12013-024-01287-9] [PMID]

[53] Zhou Q, Liu L, Zhou J, Chen Y, Xie D, Yao Y, et al. Novel insights into MALAT1 function as a microRNA sponge in NSCLC. Front Oncol. 2021;11:758653. https://doi.org/10.3389/fonc.2021.758653 [PMID]

[54] Nakagawa S, Ip JY, Shioi G, Tripathi V, Zong X, Hirose T, et al. Malat1 is not an essential component of nuclear speckles in mice. RNA. 2012;18(8):1487-99. [DOI: 10.1261/rna.033217.112] [PMID]

[55] Gutschner T, Hämmerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl). 2013;91(7):791-801. [DOI: 10.1007/s00109-013-1028-y] [PMID]

[56] Khan M, Hou S, Chen M, Lei H. Mechanisms of RNA export and nuclear retention. Wiley Interdiscip Rev RNA. 2023;14(3):e1755. [DOI: 10.1002/wrna.1755] [PMID]

[57] Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, et al. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun (Lond). 2022;42(2):117-40. [DOI: 10.1002/cac2.12254] [PMID]

[58] Chiu HS, Martínez MR, Komissarova EV, Llobet-Navas D, Bansal M, Paull EO, et al. The number of titrated microRNA species dictates ceRNA regulation. Nucleic Acids Res. 2018;46(9):4354-69. [DOI: 10.1093/nar/gky286] [PMID]

[59] Zhao Y, Teng H, Yao F, Yap S, Sun Y, Ma L. Challenges and strategies in ascribing functions to long noncoding RNAs. Cancers (Basel). 2020;12(6):1458. [DOI: 10.3390/cancers12061458] [PMID] [PMCID]

[60] Yuan Y, Ren X, Xie Z, Wang X. A quantitative understanding of microRNA-mediated competing endogenous RNA regulation. Quant Biol. 2016;4(1):47-57. [DOI: 10.1007/s40484-016-0062-5]

[61] Abubakar M, Ayyoub R, Rehman B, Zubair M, Ahmed U. Advancing cancer stem cell-targeted therapeutic applications. Proceedings of Anticancer Research. 2024;8(5):32-45. [DOI: 10.26689/par.v8i5.7043]

[62] Tsagakis I, Douka K, Birds I, Aspden JL. Long non-coding RNAs in development and disease: conservation to mechanisms. J Pathol. 2020;250(5):480-95. [DOI: 10.1002/path.5405] [PMID]

[63] Chen YM, Liu Y, Wei HY, Lv KZ, Fu P. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells. Tumour Biol. 2016;37(8):10861-70. [DOI: 10.1007/s13277-016-4909-1] [PMID]

[64] Zaman A, Sultan HM, Malik NUA, Waseem R, Farooq J. Characterization of blaNDM gene in multidrug-resistant pathogens. International Journal of General Practice Nursing. 2024;2(2):68-75. [LINK]

[65] Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014;5(6):e1287. [DOI: 10.1038/cddis.2014.249] [PMID]

[66] Usman M, Hameed Y, Ahmad M, Iqbal MJ, Maryam A, Mazhar A, et al. SHMT2 is associated with tumor purity, CD8+ T immune cells infiltration, and a novel therapeutic target in four different human cancers. Curr Mol Med. 2023;23(2):161-76. [DOI: 10.2174/1566524022666220112142409] [PMID]

[67] Zou F, Rao T, Chen W, Song T, Li T, Hu W, et al. DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7. Cell Signal. 2023;112:110893. [DOI: 10.1016/j.cellsig.2023.110893] [PMID]

[68] Vennin C, Dahmani F, Spruyt N, Adriaenssens E. Role of long non-coding RNA in cells: example of the H19/IGF2 locus. Adv Biosci Biotechnol. 2013;4(5A):34-44. [DOI: 10.4236/abb.2013.45A004]

[69] Chang S. Developmental role of H19 and IGF2 in mouse and human [doctoral dissertation]. Philadelphia (PA): University of Pennsylvania; 2021. [LINK]

[70] Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays. 2010;32(6):473-80. [DOI: 10.1002/bies.200900170] [PMID]

[71] Peperstraete E, Lecerf C, Collette J, Vennin C, Raby L, Völkel P, et al. Enhancement of breast cancer cell aggressiveness by lncRNA H19 and its miR-675 derivative: insight into shared and different actions. Cancers (Basel). 2020;12(7):1730. [DOI: 10.3390/cancers12071730] [PMID]

[72] Liu C, Chen Z, Fang J, Xu A, Zhang W, Wang Z. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol. 2016;37(1):263-70. [DOI: 10.1007/s13277-015-3779-2] [PMID]

[73] Ma Y, Shen N, Wicha MS, Luo M. The roles of the Let-7 family of microRNAs in the regulation of cancer stemness. Cells. 2021;10(9):2415. https://doi.org/10.3390/cells10092415 [PMID]

[74] Fletcher CE, Deng L, Orafidiya F, Yuan W, Lorentzen MP, Cyran OW, et al. A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Mol Cancer. 2022;21(1):82. [DOI: 10.1186/s12943-022-01540-w] [PMID]

[75] Zhang T, Huang H, Liang L, Lu H, Liang D. Long non-coding RNA (lncRNA) non-coding RNA activated by DNA damage (NORAD) knockdown alleviates airway remodeling in asthma via regulating miR-410-3p/RCC2 and inhibiting Wnt/β-catenin pathway. Heliyon. 2024;10(1):e23860. [DOI: 10.1016/j.heliyon.2023.e23860] [PMID]

[76] Yang Z, Zhao Y, Lin G, Zhou X, Jiang X, Zhao H. Noncoding RNA activated by DNA damage (NORAD): biologic function and mechanisms in human cancers. Clin Chim Acta. 2019;489:5-9. [DOI: 10.1016/j.cca.2018.11.025] [PMID]

[77] Soghli N, Yousefi T, Abolghasemi M, Qujeq D. NORAD, a critical long non-coding RNA in human cancers. Life Sci. 2021;264:118665. [DOI: 10.1016/j.lfs.2020.118665] [PMID]

[78] Huang C, Liu J, He L, Wang F, Xiong B, Li Y, et al. The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development. Bioengineered. 2021;12(2):11738-55. [DOI: 10.1080/21655979.2021.2009412] [PMID]

[79] Guo B, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. EMBO J. 2020;39(1):e102190. [DOI: 10.15252/embj.2019102190] [PMID]

[80] Li YR, Zong RQ, Zhang HY, Meng XY, Wu FX. Mechanism analysis of LINC00665 and its peptides CIP2A-BP in hepatocellular carcinoma. Front Genet. 2022;13:861096. [DOI: 10.3389/fgene.2022.861096] [PMID]

[81] Zhong C, Xie Z, Shen J, Jia Y, Duan S. LINC00665: an emerging biomarker for cancer diagnostics and therapeutics. Cells. 2022;11(9):1540. [DOI: 10.3390/cells11091540] [PMID]

[82] Itoh M, Bissell MJ. The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 2003;8(4):449-62. [DOI: 10.1023/B:JOMG.0000017431.45314.07]

[83] Ticli G, Cazzalini O, Stivala LA, Prosperi E. Revisiting the function of p21CDKN1A in DNA repair: the influence of protein interactions and stability. Int J Mol Sci. 2022;23(13):7058. [DOI: 10.3390/ijms23137058]

[84] Saramäki A, Diermeier S, Kellner R, Laitinen H, Väisänen S, Carlberg C. Cyclical chromatin looping and transcription factor association on the regulatory regions of the p21 (CDKN1A) gene in response to 1α,25-dihydroxyvitamin D3. J Biol Chem. 2009;284(12):8073-82. [DOI: 10.1074/jbc.M808090200]

[85] Sultan HM, Zubair M, Ashraf A. A comprehensive review on exploring the significance of mycoviruses. Pak J Phytopathol. 2024;36(1):249-60. [DOI: 10.33866/phytopathol.036.01.1063]

[86] Li T, Meng XL, Yang WQ. Long noncoding RNA PVT1 acts as a “sponge” to inhibit microRNA-152 in gastric cancer cells. Dig Dis Sci. 2017;62(11):3021-8. [DOI: 10.1007/s10620-017-4508-z]

[87] Zhou Q, Chen F, Zhao J, Li B, Liang Y, Pan W, et al. Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. Oncotarget. 2016;7(50):82620-33. [DOI: 10.18632/oncotarget.13012] [PMID] [PMCID]

[88] Ghetti M, Vannini I, Storlazzi CT, Martinelli G, Simonetti G. Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin. Mol Cancer. 2020;19(1):69. [DOI: 10.1186/s12943-020-01187-5] [PMID]

[89] Conte F, Fiscon G, Chiara M, Colombo T, Farina L, Paci P. Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. PLoS One. 2017;12(2):e0171661. [DOI 10.1371/journal.pone.0171661] [PMID]

[90] Abubakar M, Rehman B. Roles of mutant TP53 gene in cancer development and progression. Proceedings of Anticancer Research. 2024;8(5):165-81. [DOI: 10.26689/par.v8i5.7826]

[91] Ju JK, Han WN, Shi CL. Long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 gene (PVT1) modulates the proliferation and apoptosis of acute lymphoblastic leukemia cells by sponging miR-486-5p. Bioengineered. 2022;13(2):4587-97. [LINK]

[92] Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007;13(19):5745-55. [DOI: 10.1158/1078-0432.CCR-06-2882] [PMID]

[93] Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, et al. Promoter of lncRNA gene PVT1 is a tumor-suppressor DNA boundary element. Cell. 2018;173(6):1398-1412.e22. [DOI: 10.1016/j.cell.2018.03.068] [PMID]

[94] Vízkeleti L, Spisák S. Rewired metabolism caused by the oncogenic deregulation of MYC as an attractive therapeutic target in cancers. Cells. 2023;12(13):1745. [DOI: 10.3390/cells12131745] [PMID]

[95] Meyer KB, Maia AT, O'Reilly M, Ghoussaini M, Prathalingam R, Porter-Gill P, et al. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS Genet. 2011;7(7):e1002165. [DOI: 10.1371/journal.pgen.1002165] [PMID]

[96] Tesfaye E, Martinez-Terroba E, Bendor J, Winkler L, Olivero C, Chen K, et al. The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs. Proc Natl Acad Sci U S A. 2021;118(31):e2025539118. [DOI: 10.1073/pnas.2025539118]

[97] Meek DW. Regulation of the p53 response and its relationship to cancer. Biochem J. 2015;469(3):325-46. [DOI: 10.1042/BJ20150517]

[98] Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-dependent induction of PVT1 and miR-1204. J Biol Chem. 2012;287(4):2509-19. [DOI: 10.1074/jbc.M111.322875]

[99] Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25(5):396-415. [DOI: 10.1038/s41580-023-00694-9]

[100] Jin K, Wang S, Zhang Y, Xia M, Mo Y, Li X, et al. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis. Cell Mol Life Sci. 2019;76(21):4275-89. [DOI: 10.1007/s00018-019-03222-1] [PMID]

[101] Parolia A, Cieślik M, Chinnaiyan AM. Competing for enhancers: PVT1 fine-tunes MYC expression. Cell Res. 2018;28(8):785-6. [DOI: 10.1038/s41422-018-0064-0] [PMID]

[102] Olivero CE, Martínez-Terroba E, Zimmer J, Liao C, Tesfaye E, Hooshdaran N, et al. p53 activates the long noncoding RNA Pvt1b to inhibit Myc and suppress tumorigenesis. Mol Cell. 2020;77(4):761-74.e8. [DOI: 10.1016/j.molcel.2019.12.014] [PMID]

[103] Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43(6):904-14. [DOI: 10.1016/j.molcel.2011.08.018] [PMID]

[104] Fuschi P, Carrara M, Voellenkle C, Garcia-Manteiga JM, Righini P, Maimone B, et al. Central role of the p53 pathway in the noncoding-RNA response to oxidative stress. Aging (Albany NY). 2017;9(12):2559-86. [DOI: 10.18632/aging.101341] [PMID]

[105] Zhang A, Xu M, Mo YY. Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol. 2014;6(3):181-91. [DOI: 10.1093/jmcb/mju013] [PMID]